Arrhythmias & electrophysiology
A Multicenter Study of Stellate Ganglion Block as a Temporizing Treatment for Refractory Ventricular Arrhythmias
Authors' conclusion
In the largest cohort of patients with treatment-refractory ventricular arrhythmia, we demonstrate that SGB use was associated with a reduction in the ventricular arrhythmia burden and need for defibrillation therapy.
Study context
- Population
- Patients with refractory ventricular tachycardia (VT)/ventricular fibrillation (VF) treated with stellate ganglion blockade (SGB) at Duke and the Institute for Clinical and Experimental Medicine (Czech Republic and US), 2016–2022Duke 49, IKEM 68
- Participants
- 117 patients
- Exposure
- 24 h after SGB vs 24 h before SGB
- Outcome
- VT/VF burden and defibrillations
- Follow-up
- 24 hours before and after SGB
Methodological detailsbefore-after comparison, SGB performed at the bedside by anaesthesiologists and/or cardiologists
- Before-after comparison
- SGB performed at the bedside by anaesthesiologists and/or cardiologists
Main finding
As reported in the abstract
VT/VF episodes · 24 hours
P < 0.001
Observational data: associations, not effects.
Further findings
Median
| Outcome | Before SGB | After SGB | P value |
|---|---|---|---|
| Defibrillation events · 24 hoursCo-primary outcome of interest | 2.0 (IQR 0.0–8.0) | 0.0 (IQR 0.0–1.0) | P < 0.001 |
Original publication
A Multicenter Study of Stellate Ganglion Block as a Temporizing Treatment for Refractory Ventricular Arrhythmias. JACC Clin Electrophysiol. Published 14 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →